This study will create new knowledge by critically evaluating 2 promising KLK3 (PSA) SNP biomarkers, at both the molecular functional and diagnostic level, with a view to their incorporation in a risk model that will improve the existing PSA test and allow the detection of prostate cancer at an earlier stage and/or selectively identify prostate cancers that should be treated from those that grow slowly and would not surface or cause significant symptoms during the lifetime of the patients in multiethnic populations. The outcomes from this study therefore may have the potential to save or improve lives when used to screen/test men for prostate cancer and guide decisions about treatment.
The objective of this project is to elucidate the functional significance of these newly discovered SNPs in prostate cancer aetiology, and systematically investigate the association of non-synonymous KLK3 SNPs with prostate cancer predisposition and prognosis.